AstraZeneca: exclusive licensing agreement with CSPC

(CercleFinance.com) - AstraZeneca strengthens its cardiovascular portfolio with an agreement for a new preclinical lipid-lowering therapy.


AstraZeneca has entered into an exclusive licensing agreement with CSPC Pharmaceutical Group (CSPC) to advance the development of a novel, early-stage small molecule lipoprotein disruptor that has the potential to offer additional benefits to patients with dyslipidemia.

Under the terms of the agreement, AstraZeneca will have access to CSPC's preclinical small molecule candidate, YS2302018, an oral Lp(a) disruptor, with the aim of developing it as a novel lipid-lowering therapy with potential in a range of cardiovascular disease indications, alone or in combination, including with the oral PCSK9 inhibitor AZD0780.

Sharon Barr, Executive Vice President and Head of Biopharmaceutical R&D at AstraZeneca, commented: 'This asset is an important addition to our cardiovascular pipeline and could help patients manage dyslipidemia and associated cardiometabolic diseases more effectively'.

Copyright (c) 2024 CercleFinance.com. All rights reserved.